Harris Erik
SEC CIK 1780113 · EDGAR
BoughtSold
Most active insiders at RARE, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Horn Howard | CFO | — | $1.33M |
| 2 | KAKKIS EMIL D | Pres, CEO, Dir | — | $1.24M |
| 3 | Parschauer Karah Herdman | EVP, CLO | — | $487.9K |
| 4 | Harris Erik | EVP, Chief Commercial Off | — | $240.3K |
| 5 | Pinion John Richard | See Remarks | — | $228.7K |
| 6 | Crombez Eric | EVP, Chief Medical Off | — | $168.8K |
| 7 | SULIMAN SHEHNAAZ | Dir | — | $144.2K |
| 8 | Huizenga Theodore Alan | SVP, CAO | — | $59.8K |
| 9 | Sanders Corazon (Corsee) D. | Dir | — | $50.1K |
| 10 | Ray Amrit | Dir | — | — |
Transactions 20
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-04-20 17:13 | 2026-04-16 | RARE | Ultragenyx Pharmaceutical Inc. | Harris Erik | EVP, Chief Commercial Off | A - Grant | $0.00 | +28.9K | 118.4K | +32% | $0 |
| 2026-03-03 | 2026-03-01 | RARE | Ultragenyx Pharmaceutical Inc. | Harris Erik | EVP, Chief Commercial Off | A - Grant | $0.00 | +11.6K | 99.5K | +13% | $0 | |
| 2026-03-03 | 2026-03-02 | RARE | Ultragenyx Pharmaceutical Inc. | Harris Erik | EVP, Chief Commercial Off | S - Sale | $22.80 | -10.5K | 89.5K | -11% | -$240.3K | |
| D | 2025-11-21 | 2025-11-19 | RZLT | Rezolute, Inc. | Harris Erik | Dir | A - Grant | $0.00 | +21.0K | 21.0K | New | $0 |
| DM | 2025-03-04 | 2025-03-01 | RARE | Ultragenyx Pharmaceutical Inc. | Harris Erik | EVP, Chief Commercial Off | A - Grant | $0.00 | +35.3K | 84.0K | +72% | $0 |
| D | 2025-03-04 | 2025-03-03 | RARE | Ultragenyx Pharmaceutical Inc. | Harris Erik | EVP, Chief Commercial Off | S - Sale | $42.10 | -15.1K | 87.9K | -15% | -$635.8K |
| D | 2024-06-04 | 2024-05-31 | DNLI | Denali Therapeutics Inc. | Harris Erik | Dir | A - Grant | $0.00 | +5,967 | 17.1K | +54% | $0 |
| D | 2024-03-05 | 2024-03-01 | RARE | Ultragenyx Pharmaceutical Inc. | Harris Erik | EVP, Chief Commercial Off | S - Sale | $53.76 | -4,768 | 67.2K | -7% | -$256.3K |
| DM | 2024-03-05 | 2024-03-01 | RARE | Ultragenyx Pharmaceutical Inc. | Harris Erik | EVP, Chief Commercial Off | A - Grant | $0.00 | +20.4K | 70.7K | +40% | $0 |
| 2023-09-06 | 2023-09-05 | RARE | Ultragenyx Pharmaceutical Inc. | Harris Erik | EVP, Chief Commercial Off | S - Sale | $37.96 | -6,000 | 51.3K | -10% | -$227.8K | |
| 2023-06-21 | 2023-06-19 | RARE | Ultragenyx Pharmaceutical Inc. | Harris Erik | EVP, Chief Commercial Off | S - Sale | $48.20 | -305 | 57.3K | -0.5% | -$14.7K | |
| D | 2023-06-05 | 2023-06-01 | DNLI | Denali Therapeutics Inc. | Harris Erik | Dir | A - Grant | $0.00 | +4,216 | 11.1K | +61% | $0 |
| DM | 2023-03-03 | 2023-03-01 | RARE | Ultragenyx Pharmaceutical Inc. | Harris Erik | EVP, Chief Commercial Off | A - Grant | $0.00 | +24.7K | 38.8K | +174% | $0 |
| D | 2023-03-03 | 2023-03-01 | RARE | Ultragenyx Pharmaceutical Inc. | Harris Erik | EVP, Chief Commercial Off | S - Sale | $45.25 | -3,664 | 57.3K | -6% | -$165.8K |
| 2022-06-22 | 2022-06-19 | RARE | Ultragenyx Pharmaceutical Inc. | Harris Erik | EVP, Chief Commercial Off | S - Sale | $54.78 | -295 | 36.2K | -0.8% | -$16.2K | |
| D | 2022-03-03 | 2022-03-01 | RARE | Ultragenyx Pharmaceutical Inc. | Harris Erik | EVP, Chief Commercial Off | S - Sale | $66.62 | -2,713 | 22.3K | -11% | -$180.7K |
| D | 2022-03-03 | 2022-03-01 | RARE | Ultragenyx Pharmaceutical Inc. | Harris Erik | EVP, Chief Commercial Off | A - Grant | $0.00 | +14.0K | 36.3K | +63% | $0 |
| D | 2022-02-07 | 2022-02-03 | DNLI | Denali Therapeutics Inc. | Harris Erik | Dir | A - Grant | $0.00 | +6,869 | 6,869 | New | $0 |
| 2021-10-18 | 2021-10-14 | RARE | Ultragenyx Pharmaceutical Inc. | Harris Erik | EVP, Chief Commercial Off | S - Sale | $81.14 | -303 | 25.0K | -1% | -$24.6K | |
| 2021-07-08 | 2021-07-06 | RARE | Ultragenyx Pharmaceutical Inc. | Harris Erik | EVP, Chief Commercial Off | S - Sale | $91.53 | -375 | 25.3K | -1% | -$34.3K |
Purchase Sale Sale after option exercise All abbreviations